Last reviewed · How we verify
Biological: mRNA-1273 — Competitive Intelligence Brief
phase 2
mRNA vaccine
SARS-CoV-2 spike protein
Infectious Disease
Biologic
Live · refreshed every 30 min
Target snapshot
Biological: mRNA-1273 (Biological: mRNA-1273) — ModernaTX, Inc.. mRNA-based vaccine that encodes for the SARS-CoV-2 spike protein
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Biological: mRNA-1273 TARGET | Biological: mRNA-1273 | ModernaTX, Inc. | phase 2 | mRNA vaccine | SARS-CoV-2 spike protein | |
| batch 1 of Ad5-nCoV | batch 1 of Ad5-nCoV | Jiangsu Province Centers for Disease Control and Prevention | marketed | viral vector vaccine | SARS-CoV-2 spike protein | |
| Influenza | Influenza and COVID-19 Combination A | BioNTech | marketed | Non-Standardized Plant Allergenic Extract [EPC] | SARS-CoV-2 spike protein and influenza hemagglutinin protein | |
| Tozinameran 6 months to 4 years of age | tozinameran-6-months-to-4-years-of-age | Pfizer | marketed | vaccine | SARS-CoV-2 spike protein | |
| Tozinameran 12 Years of age and older | tozinameran-12-years-of-age-and-older | Pfizer | marketed | vaccine | SARS-CoV-2 spike protein | |
| MVC-COV1901(3 Months) | MVC-COV1901(3 Months) | Taoyuan General Hospital | marketed | Protein subunit vaccine | SARS-CoV-2 spike protein | |
| Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose | variant-adapted-bnt162b2-omicron-xbb-1-5-10-microgram-dose | Pfizer | marketed | mRNA vaccine | SARS-CoV-2 spike protein |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (mRNA vaccine class)
- Pfizer · 12 drugs in this class
- ModernaTX, Inc. · 11 drugs in this class
- BioNTech SE · 5 drugs in this class
- Jules Bordet Institute · 5 drugs in this class
- Tan Tock Seng Hospital · 2 drugs in this class
- Clover Biopharmaceuticals AUS Pty · 1 drug in this class
- CanSino Biologics Inc. · 1 drug in this class
- Assistance Publique - Hôpitaux de Paris · 1 drug in this class
- CSPC Megalith Biopharmaceutical Co.,Ltd. · 1 drug in this class
- Jens D Lundgren, MD · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Biological: mRNA-1273 CI watch — RSS
- Biological: mRNA-1273 CI watch — Atom
- Biological: mRNA-1273 CI watch — JSON
- Biological: mRNA-1273 alone — RSS
- Whole mRNA vaccine class — RSS
Cite this brief
Drug Landscape (2026). Biological: mRNA-1273 — Competitive Intelligence Brief. https://druglandscape.com/ci/biological-mrna-1273. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab